By PPN News Staff
The FDA approved bevacizumab-bvzr (Zirabev, Pfizer), a biosimilar to bevacizumab (Avastin, Genentech), for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic nonsquamous non-small cell lung cancer (NSCLC); recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.